Epilepsy, Generalized Clinical Trial
— C2CEDRCTOfficial title:
Clinic to Community© Program for Adults With Epilepsy Admitted to Emergency Departments: A Randomized Controlled Trial
Verified date | January 2024 |
Source | Lawson Health Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Analysis of emergency department (ED) visits with a billing code for 'epilepsy' or 'seizure' found up to 37% are eligible for deferral. This study is a randomized controlled trial (RCT) of the Clinic To Community© program (C2C) as an intervention for adults with epilepsy visiting emergency departments at a mid size hospital in Ontario, Canada. Participants in the intervention arm receive patient education to improve knowledge of epilepsy and access to community-based services. Participants in the control group are wait-listed and receive patient education 12 months later. The study objective is to successfully implement, recruit and retain participants for this intervention and evaluate whether C2C will reduce the frequency of ED visits, reduce felt stigma and improve quality of life, epilepsy knowledge, and self-management skills.
Status | Completed |
Enrollment | 9 |
Est. completion date | December 11, 2023 |
Est. primary completion date | December 11, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Adults (aged =18 years) visiting a participating ED for a seizure or an epilepsy-related concern. 2. Adults on anti-seizure medication prior to coming to the ED or prescribed anti-seizure medication at the ED. 3. Providing informed consent and having sufficient English language skills to complete questionnaires and participate in the intervention. Exclusion Criteria: 1. Previous participation in the C2C program. 2. Known diagnosis of psychogenic non-epileptic seizures (PNES). |
Country | Name | City | State |
---|---|---|---|
Canada | London Health Sciences Centre | London | Ontario |
Lead Sponsor | Collaborator |
---|---|
Lawson Health Research Institute | Ontario Brain Institute |
Canada,
Bautista RE, Glen ET, Wludyka PS, Shetty NK. Factors associated with utilization of healthcare resources among epilepsy patients. Epilepsy Res. 2008 May;79(2-3):120-9. doi: 10.1016/j.eplepsyres.2008.01.003. Epub 2008 Mar 12. — View Citation
Bowen JM, Snead OC, Chandra K, Blackhouse G, Goeree R. Epilepsy care in ontario: an economic analysis of increasing access to epilepsy surgery. Ont Health Technol Assess Ser. 2012;12(18):1-41. Epub 2012 Jul 1. — View Citation
Couldridge L, Kendall S, March A. A systematic overview--a decade of research'. The information and counselling needs of people with epilepsy. Seizure. 2001 Dec;10(8):605-14. doi: 10.1053/seiz.2001.0652. — View Citation
Kapoor, Deepa, Joubert, Gary, Thind, Amardeep, Secco, Mary, Speechley, Kathy Nixon. Number of Potentially Deferrable Patients Presenting to Emergency Departments in London with Seizures. Epilepsia 2007; Vol 48, Supplement 6
Noble AJ, Mathieson A, Ridsdale L, Holmes EA, Morgan M, McKinlay A, Dickson JM, Jackson M, Hughes DA, Goodacre S, Marson AG. Developing patient-centred, feasible alternative care for adult emergency department users with epilepsy: protocol for the mixed-methods observational 'Collaborate' project. BMJ Open. 2019 Nov 2;9(11):e031696. doi: 10.1136/bmjopen-2019-031696. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Effect on quality of life using World Health Organization Quality of Life (WHOQOL) | Change from baseline measured by World Health Organization Quality of Life (WHOQOL) - Abbreviated (BREF), 30-item measure of quality of life, generic-HRQOL instrument. | Baseline (0) and 12 months | |
Other | Effect on activities of daily living using Sheehan Disability Scale | Change from baseline measured by the Sheehan Disability Scale is 5-items for patient-rated measure of disability and impairment. | Baseline (0) and 12 months | |
Other | Effect on anxiety using Generalized Anxiety Disorder 7-item (GAD-7) scale | Change from baseline using the Generalized Anxiety Disorder 7-item (GAD-7) scale, 7-item scale evaluating generalized anxiety. Generates an overall anxiety score, with scores above 10 indicative of moderate-severe anxiety. | Baseline (0) and 12 months | |
Other | Effect on depressive symptoms based on Quick Inventory of Depressive Symptomatology | Change from baseline using the Quick Inventory of Depressive Symptomatology, 14-item scale evaluating depressive symptoms. | Baseline (0) and 12 months | |
Other | Effect on sleep quality using Pittsburgh Sleep Quality Index (25-items) | Change from baseline measured by the Pittsburgh Sleep Quality Index, 25-item scale evaluating sleep quality. | Baseline (0) and 12 months | |
Other | Effect on suicide ideation using Columbia-Suicide Severity Rating Scale (C-SSRS) Screener | Change from baseline measured by the C-SSRS Screener, a 6-item scale evaluating suicidal ideation. | Baseline (0) and 12 months | |
Other | Effect on Psychiatric comorbidities using Brief Symptom Inventory | Change from baseline measured by 53-items covering nine symptom dimensions: Somatization, Obsession-Compulsion, Interpersonal Sensitivity, Depression, Anxiety, Hostility, Phobic anxiety, Paranoid ideation and Psychoticism; and three global indices of distress: Global Severity Index, Positive Symptom Distress Index, and Positive Symptom Total. The global indices measure current or past level of symptomatology, intensity of symptoms, and number of reported symptoms, respectively | Baseline (0) and 12 months | |
Primary | Rate of engagement with the Clinic To Community© (C2C) program | Evaluated by rate of ED referrals, rate of recruitment, rate of retention, and proportion who receive support education. | Throughout study completion, approximately 2 years | |
Secondary | Frequency of epilepsy-related emergency department (ED) visits over the next 12 months | Change from baseline in frequency of ED visits and health care utilization, adapted from the Canadian Community Health Survey | Baseline (0), and 12 months | |
Secondary | Effect of participation in C2C on felt stigma using "Stigma Scale of Epilepsy" | Change from baseline in using the Stigma Scale of Epilepsy, 3-item scale asking: "Because of epilepsy, (1) other people are uncomfortable with me; (2) treat me as inferior; (3) prefer to avoid me." Each of those questions is scored on a four-point scale:
0 not at all; 1 yes, maybe; 2 yes, probably; 3 yes, definitely. Total scores range from 0 to 9 and categorized as not stigmatized (score of 0), mild-moderate (1-6) and highly stigmatized (7-9). |
Baseline (0) and 12 months | |
Secondary | Effect of participation in C2C on felt stigma using "Epilepsy Stigma Scale" | Change from baseline measured by Epilepsy Stigma Scale, a 10-item measure evaluating stigma. Items are measured on a 7-point Likert Scale, from "strongly agree" to "strongly disagree". | Baseline (0) and 12 months | |
Secondary | Effect of participation in C2C on self-management skills | Change from baseline measured by the Adult Epilepsy Self-Management Measurement Instrument (AESMMI-65) This measure is a 65-item scale assessing the frequency of use of epilepsy self-management practises. Contains seven domains: 1) healthcare communication, 2) treatment management, 3) coping, 4) social support, 5) seizure tracking, 6) wellness, and 7) seizure response. | Baseline (0) and 12 months | |
Secondary | Effect of participation in C2C on quality of life | Change from baseline measured by Quality of Life in Epilepsy Inventory (QOLIE 10), a 10-item scaled evaluating quality of life in adults with epilepsy. Responses range from "all of the time" to "none of the time" | Baseline (0) and 12 months | |
Secondary | Effect of participation in C2C on epilepsy knowledge | Change from baseline on the "Thinking About Epilepsy Questionnaire" knowledge subscale. Knowledge is assessed by answering true/false/I don't know | Baseline (0) and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00162981 -
Clobazam in Subjects With Lennox-Gastaut Syndrome
|
Phase 2 | |
Completed |
NCT00236886 -
Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients
|
Phase 3 | |
Recruiting |
NCT05477121 -
Severity: Quantifying the Severity of Generalized Tonic-clonic Seizures (GTCS) With Connected Devices
|
||
Recruiting |
NCT04959019 -
Exercise for Memory Rehabilitation in Epilepsy
|
N/A | |
Completed |
NCT00231556 -
A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy
|
Phase 3 | |
Completed |
NCT04439656 -
Detecting Absence Seizures Using Eye Tracking
|
||
Completed |
NCT00319501 -
Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control Episodes of Acute Repetitive Seizures.
|
Phase 3 | |
Completed |
NCT05241678 -
Evaluation of the 24/7 EEG™ SubQ System in Subjects With Uncontrolled Genetic Generalised Epilepsy Syndrome
|
||
Completed |
NCT00266604 -
A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy
|
Phase 4 | |
Completed |
NCT00518713 -
Clobazam in Patients With Lennox-Gastaut Syndrome
|
Phase 3 | |
Recruiting |
NCT06399952 -
Baker Gordon Syndrome Natural History Study
|
||
Completed |
NCT05297695 -
Helicobacter Pylori Eradication Therapy for Epileptic Children
|
Phase 2/Phase 3 |